Results 151 to 160 of about 85,902 (266)

Antibody-lectin chimeras for glyco-immune checkpoint blockade. [PDF]

Nat Biotechnol
Stark JC, Gray MA, Ibarlucea-Benitez I, Lustig M, Bond A, Cho B, Govil I, Luu T, Priestley MJ, Veth TS, Errington WJ, Bruncsics B, Ribi MK, Williams LA, Sarkar CA, Wisnovsky S, Riley NM, Morrissey MA, Valerius T, Ravetch JV, Bertozzi CR.   +20 more
europepmc   +1 more source

Engineering Oncolytic Virus‐Armed Macrophages for Enhanced Cancer Immunotherapy

Advanced Science, EarlyView.
ZIFOA‐M is engineered by conjugating oncolytic adenovirus‐loaded ZIF‐8 nanoparticles onto macrophage surfaces via bioorthogonal chemistry. Upon tumor infiltration, the platform releases OA to downregulate CD47/CD24 on tumor cells, restoring macrophage phagocytosis.
Jilong Wang, Ning Lu, Zhuo Yan, Luyi Ye, Luyao Bai, Shanshan Yuan, Yuting Zhu, Yiru Xiong, Yongheng Bai, Yaping Chen, Junjie Deng   +10 more
wiley   +1 more source

Pharmacologic targeting of the dopamine D2 receptor impacts the efficacy of immune checkpoint blockade in melanoma. [PDF]

J Immunother Cancer
Gregory M, Hackett JB, Hughes S, Muñiz MC, Ayoub S, Boerner A, Alrabaa H, Taylor L, Rivera B, Holland H, Dyson G, Daveluy S, Gibson H.   +12 more
europepmc   +1 more source

T Cell‐Independent Role of PD‐L1 in Kidney Repair: Mitigation of Tubular DNA Damage via PD‐L1/BRCA1 Interaction Following AKI

Advanced Science, EarlyView.
PD‐L1 is primarily expressed in renal tubules and upregulated in both murine models of AKI and renal biopsy samples from patients with AKI. PD‐L1 can promote adaptive TECs repair through interacting with BRCA1, independent of its canonical immunomodulatory function of T cells, and PD‐L1 supplementation may represent a promising therapeutic strategy for
Wei Jiang, Tao‐Tao Tang, Wei‐Jie Ni, Jin‐Xuan Wei, Liang‐Yun‐Zi Jiang, Qing Yin, Yi‐Lin Zhang, Zuo‐Lin Li, Yi Wen, Xin‐Lu Wang, Jun‐Yuan Shen, Xiao‐Jun Ouyang, Ming‐Zhu Zheng, Jian Xu, Xiaofei An, Lin‐Li Lv, Bi‐Cheng Liu, Bin Wang   +17 more
wiley   +1 more source

Immune Checkpoint Blockade in Hematological Malignancies: Current Status and Future Directions. [PDF]

Cancers (Basel)
Lau HC, Kwong YL.
europepmc   +1 more source

Self‐Accelerating Bimetallic Peroxide Nanozymes for Cascade‐Amplified Pyroptosis‐Immunotherapy

Advanced Science, EarlyView.
Acidic tumor microenvironment‐responsive CuZnONPs enable triple‐combination therapy via self‐supplying H2O2, cascade nanozyme activities for ROS burst, and Zn2+‐activated pyroptosis, synergizing catalytic therapy with immunotherapy to convert cold tumors into hot ones.
Xuanyi Lu, Liang Li, Siyu Pan, Yuehan Jian, Yuhan Chen, Wenjie Yang, Guang Song, Xueyang Fang, Ping'an Ma, Lijun Jiang   +9 more
wiley   +1 more source

Immune checkpoint blockade in cancer: current insights and future horizons. [PDF]

Discov Oncol
Saman H, Makni-Maalej K, El-Ella DMA, Al-Tamimi MY, AbuHaweeleh MN, Abuhayeh N, Ismail MA, Prabhu KS, Fernandes Q, Jabi T, Elhussein R, Inchakalody VP, Merhi M, Dermime S, Uddin S.   +14 more
europepmc   +1 more source

Adverse Events Associated with Immune Checkpoint Blockade [PDF]

New England Journal of Medicine, 2018
Jan-Willem, Cohen Tervaert, Carrie, Ye, Elaine, Yacyshyn   +2 more
openaire   +6 more sources

“Membrane‐Guided” Repair Strategy: Precision Delivery of GGT1 Degrader for Targeted Repair and Regeneration of Spinal Cord Neurons

Advanced Science, EarlyView.
This study confirms that GGT1 is a key driver of neuronal ferroptosis following spinal cord injury. We developed NSCm@EA, a biomimetic delivery system coated with neural stem cell membranes, for precise delivery of enocyanin to injured neurons. By combining targeted delivery with ubiquitination degradation mechanisms, this system promotes MGRN1 ...
Tao Yang, Lei Ye, Peigen Xie, Tao Song, Jian Chen, Heng Zhao, Zhengshan Liu, Xi Chen, Jianing Ding, Xintian Ding, Ao Shao, Miaomiao Wu, Fengdong Zhao, Siyue Tao, Tao You   +14 more
wiley   +1 more source

Amendment to Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. [PDF]

J Clin Invest
Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y, Li Y, Wan C, So KM, Liu D, Frieden M, Fang Y, Mosley AL, He X, Zhang X, Sandusky GE, Liu Y, Meroueh SO, Zhang C, Wijeratne AB, Huang C, Ji G, Lu X.   +22 more
europepmc   +1 more source